Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab rechallenge after ipilimumab priming and SBRT in advanced NSCLC
2022-500713-79-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cemiplimab and ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical benefit rate. Planned start Oct 2022; status: authorised.
02
Drugs
cemiplimabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-500713-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500713-79-00.